CSL CSLLY Stock
CSL Price Chart
CSL CSLLY Financial and Trading Overview
| CSL stock price | 33.6 USD |
| Previous Close | 32.6 USD |
| Open | 33.38 USD |
| Bid | 33.22 USD x 30000 |
| Ask | 33.32 USD x 180000 |
| Day's Range | 33.23 - 33.38 USD |
| 52 Week Range | 16.01 - 36.29 USD |
| Volume | 4.91K USD |
| Avg. Volume | 126.96K USD |
| Market Cap | 64.02B USD |
| Beta (5Y Monthly) | 0.081 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.34 USD |
| Forward Dividend & Yield | 0.71 (2.13%) |
| Ex-Dividend Date | September 10, 2026 |
| 1y Target Est | 34 USD |
CSLLY Valuation Measures
| Enterprise Value | 74.78B USD |
| Trailing P/E | N/A |
| Forward P/E | 19.83065 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0524507 |
| Price/Book (mrq) | 4.317571 |
| Enterprise Value/Revenue | 4.734 |
| Enterprise Value/EBITDA | 14.726 |
Trading Information
CSL Stock Price History
| Beta (5Y Monthly) | 0.081 |
| 52-Week Change | -6.54% |
| S&P500 52-Week Change | 13.72% |
| 52 Week High | 36.29 USD |
| 52 Week Low | 16.01 USD |
| 50-Day Moving Average | 30.23 USD |
| 200-Day Moving Average | 25.3 USD |
CSLLY Share Statistics
| Avg. Volume (3 month) | 126.96K USD |
| Avg. Daily Volume (10-Days) | 59.61K USD |
| Shares Outstanding | 1.92B |
| Float | 1.91B |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.0080% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.92 |
| Trailing Annual Dividend Yield | 8.95% |
| 5 Year Average Dividend Yield | 144.00% |
| Payout Ratio | 0.4457 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | -16.32% |
| Operating Margin (ttm) | 21.48% |
| Gross Margin | 51.11% |
| EBITDA Margin | 32.14% |
Management Effectiveness
| Return on Assets (ttm) | 7.25% |
| Return on Equity (ttm) | -15.83% |
Income Statement
| Revenue (ttm) | 15.8B USD |
| Revenue Per Share (ttm) | 8.19 USD |
| Quarterly Revenue Growth (yoy) | 5.50% |
| Gross Profit (ttm) | 8.07B USD |
| EBITDA | 5.08B USD |
| Net Income Avi to Common (ttm) | -2579000064 USD |
| Diluted EPS (ttm) | -1.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.51B USD |
| Total Cash Per Share (mrq) | 0.79 USD |
| Total Debt (mrq) | 10.9B USD |
| Total Debt/Equity (mrq) | 66.82 USD |
| Current Ratio (mrq) | 2.21 |
| Book Value Per Share (mrq) | 7.72425 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.51B USD |
| Levered Free Cash Flow (ttm) | 1.89B USD |
Profile of CSL
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 655 Elizabeth Street |
| ZIP | 3000 |
| Phone | 61 3 9389 1911 |
| Website | https://www.csl.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29000 |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Q&A For CSL Stock
What is a current CSLLY stock price?
CSL CSLLY stock price today per share is 33.6 USD.
How to purchase CSL stock?
You can buy CSLLY shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CSL?
The stock symbol or ticker of CSL is CSLLY.
Which industry does the CSL company belong to?
The CSL industry is Biotechnology.
How many shares does CSL have in circulation?
The max supply of CSL shares is 1.92B.
What is CSL Price to Earnings Ratio (PE Ratio)?
CSL PE Ratio is now.
What was CSL earnings per share over the trailing 12 months (TTM)?
CSL EPS is -1.34 USD over the trailing 12 months.
Which sector does the CSL company belong to?
The CSL sector is Healthcare.
